Does the media favor LEGN or JBIO?

In the previous week, Jade Biosciences had 3 more articles in the media than Legend Biotech. MarketBeat recorded 11 mentions for Jade Biosciences and 8 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.33 beat Jade Biosciences' score of 0.26 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, XENE or JBIO?

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xenon Pharmaceuticals N/A N/A -$345.91M -$4.74 N/A Jade Biosciences N/A N/A -$127.41M -$1.92 N/A

Is XENE or JBIO more profitable?

Xenon Pharmaceuticals' return on equity of -43.98% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -43.98% -41.72% Jade Biosciences N/A -49.11% -45.62%

Does the media favor XENE or JBIO?

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 11 articles in the media. Xenon Pharmaceuticals' average media sentiment score of 1.20 beat Jade Biosciences' score of 0.26 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AMLX or JBIO more profitable?

Jade Biosciences' return on equity of -49.11% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Jade Biosciences N/A -49.11% -45.62%

Does the media refer more to AMLX or JBIO?

In the previous week, Jade Biosciences had 6 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 11 mentions for Jade Biosciences and 5 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Jade Biosciences' score of 0.26 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ELVN or JBIO?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Jade Biosciences N/A N/A -$127.41M -$1.92 N/A

Is ELVN or JBIO more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Jade Biosciences N/A -49.11% -45.62%

Does the media favor ELVN or JBIO?

In the previous week, Jade Biosciences had 7 more articles in the media than Enliven Therapeutics. MarketBeat recorded 11 mentions for Jade Biosciences and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.12 beat Jade Biosciences' score of 0.26 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNLI or JBIO more profitable?

Jade Biosciences' return on equity of -49.11% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -55.27% -44.24% Jade Biosciences N/A -49.11% -45.62%

Does the media prefer DNLI or JBIO?

In the previous week, Jade Biosciences had 9 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Jade Biosciences and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Jade Biosciences' score of 0.26 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Jade Biosciences (JBIO) Competitors

$14.12 +0.35 (+2.54%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$14.12 +0.01 (+0.04%)

As of 10/2/2026 07:30 PM Eastern

Compare

JBIO vs. LEGN, XENE, AMLX, ELVN, and DNLI

Should you buy Jade Biosciences stock or one of its competitors? Jade Biosciences's main competitors and comparable companies include Legend Biotech (LEGN), Xenon Pharmaceuticals (XENE), Amylyx Pharmaceuticals (AMLX), Enliven Therapeutics (ELVN), and Denali Therapeutics (DNLI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jade Biosciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Jade Biosciences had 3 more articles in the media than Legend Biotech. MarketBeat recorded 11 mentions for Jade Biosciences and 8 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.33 beat Jade Biosciences' score of 0.26 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech presently has a consensus target price of $55.79, suggesting a potential upside of 200.41%. Jade Biosciences has a consensus target price of $51.75, suggesting a potential upside of 266.50%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Legend Biotech has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Jade Biosciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.50	-$296.80M	-$0.25	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Jade Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Jade Biosciences	N/A	-49.11%	-45.62%

Summary

Jade Biosciences beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Jade Biosciences compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Xenon Pharmaceuticals' return on equity of -43.98% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Jade Biosciences	N/A	-49.11%	-45.62%

Xenon Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Xenon Pharmaceuticals currently has a consensus price target of $70.27, suggesting a potential upside of 84.82%. Jade Biosciences has a consensus price target of $51.75, suggesting a potential upside of 266.50%. Given Jade Biosciences' higher probable upside, analysts clearly believe Jade Biosciences is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 11 articles in the media. Xenon Pharmaceuticals' average media sentiment score of 1.20 beat Jade Biosciences' score of 0.26 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xenon Pharmaceuticals and Jade Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Jade Biosciences compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, Jade Biosciences had 6 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 11 mentions for Jade Biosciences and 5 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Jade Biosciences' score of 0.26 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals presently has a consensus target price of $38.86, suggesting a potential upside of 39.82%. Jade Biosciences has a consensus target price of $51.75, suggesting a potential upside of 266.50%. Given Jade Biosciences' higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences' return on equity of -49.11% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Jade Biosciences	N/A	-49.11%	-45.62%

Amylyx Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Jade Biosciences has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	35.44	-$144.74M	-$1.43	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Jade Biosciences beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Enliven Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

Enliven Therapeutics' return on equity of -18.55% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Jade Biosciences	N/A	-49.11%	-45.62%

95.1% of Enliven Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Jade Biosciences had 7 more articles in the media than Enliven Therapeutics. MarketBeat recorded 11 mentions for Jade Biosciences and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.12 beat Jade Biosciences' score of 0.26 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Enliven Therapeutics currently has a consensus price target of $74.44, indicating a potential upside of 58.49%. Jade Biosciences has a consensus price target of $51.75, indicating a potential upside of 266.50%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Enliven Therapeutics and Jade Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Jade Biosciences had 9 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Jade Biosciences and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Jade Biosciences' score of 0.26 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Jade Biosciences has lower revenue, but higher earnings than Denali Therapeutics. Jade Biosciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$3.60M	887.05	-$512.54M	-$2.84	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

92.9% of Denali Therapeutics shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Denali Therapeutics presently has a consensus target price of $35.85, suggesting a potential upside of 79.23%. Jade Biosciences has a consensus target price of $51.75, suggesting a potential upside of 266.50%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences' return on equity of -49.11% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Jade Biosciences	N/A	-49.11%	-45.62%

Summary

Jade Biosciences beats Denali Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JBIO vs. The Competition

Export

Metric	Jade Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$897.99M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-7.35	13.06	275.66	26.04
Price / Sales	N/A	1,295.79	609.46	91.89
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	2.09	16.63	10.93	6.31
Net Income	-$127.41M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-2.08%	-2.99%	-2.00%	-1.66%
1 Month Performance	-28.87%	-10.60%	-6.15%	-4.50%
1 Year Performance	59.37%	19.44%	7.44%	2.06%

Jade Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JBIO Jade Biosciences	2.0056 of 5 stars	$14.12 +2.5%	$51.75 +266.5%	+69.5%	$897.99M	N/A	N/A	55	News Coverage Analyst Forecast
LEGN Legend Biotech	3.5577 of 5 stars	$19.06 +3.3%	$53.14 +178.8%	-42.5%	$3.69B	$1.27B	N/A	2,965	News Coverage Insider Trade
XENE Xenon Pharmaceuticals	3.802 of 5 stars	$38.06 +4.1%	$70.93 +86.4%	-3.0%	$3.68B	$7.50M	N/A	370	Trending News Analyst Upgrade Insider Trade High Trading Volume
AMLX Amylyx Pharmaceuticals	3.3871 of 5 stars	$30.14 -1.5%	$38.86 +28.9%	+109.1%	$3.36B	N/A	N/A	136	News Coverage Positive News
ELVN Enliven Therapeutics	2.9041 of 5 stars	$45.17 -2.0%	$75.00 +66.0%	+135.8%	$3.31B	N/A	N/A	67	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JBIO) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jade Biosciences (JBIO) Competitors

JBIO vs. LEGN, XENE, AMLX, ELVN, and DNLI

How does Jade Biosciences compare to Legend Biotech?

Summary

How does Jade Biosciences compare to Xenon Pharmaceuticals?

Summary

How does Jade Biosciences compare to Amylyx Pharmaceuticals?

Summary

How does Jade Biosciences compare to Enliven Therapeutics?

Summary

How does Jade Biosciences compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jade Biosciences (JBIO) Competitors

JBIO vs. LEGN, XENE, AMLX, ELVN, and DNLI

How does Jade Biosciences compare to Legend Biotech?

Do insiders & institutionals hold more shares of LEGN or JBIO?

Does the media favor LEGN or JBIO?

Do analysts recommend LEGN or JBIO?

Which has more volatility and risk, LEGN or JBIO?

Which has stronger earnings & valuation, LEGN or JBIO?

Is LEGN or JBIO more profitable?

Summary

How does Jade Biosciences compare to Xenon Pharmaceuticals?

Do insiders and institutionals hold more shares of XENE or JBIO?

Is XENE or JBIO more profitable?

Which has more volatility & risk, XENE or JBIO?

Do analysts prefer XENE or JBIO?

Which has higher valuation & earnings, XENE or JBIO?

Does the media favor XENE or JBIO?

Summary

How does Jade Biosciences compare to Amylyx Pharmaceuticals?

Does the media refer more to AMLX or JBIO?

Do analysts prefer AMLX or JBIO?

Is AMLX or JBIO more profitable?

Which has more risk and volatility, AMLX or JBIO?

Which has preferable earnings and valuation, AMLX or JBIO?

Do institutionals & insiders hold more shares of AMLX or JBIO?

Summary

How does Jade Biosciences compare to Enliven Therapeutics?

Which has more risk & volatility, ELVN or JBIO?

Is ELVN or JBIO more profitable?

Do institutionals & insiders believe in ELVN or JBIO?

Does the media favor ELVN or JBIO?

Which has better valuation & earnings, ELVN or JBIO?

Do analysts recommend ELVN or JBIO?

Summary

How does Jade Biosciences compare to Denali Therapeutics?

Does the media prefer DNLI or JBIO?

Which has more volatility & risk, DNLI or JBIO?

Which has preferable earnings and valuation, DNLI or JBIO?

Do institutionals and insiders have more ownership in DNLI or JBIO?

Do analysts recommend DNLI or JBIO?

Is DNLI or JBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools